Prelude Capital Management’s Qiagen QGEN Stock Holding History

Prelude Capital Management’s Portfolio QGEN Stock Details QGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,829	Closed	-$101K	–	1922
2019 Q4	$101K	Buy	+2,829	New	+$105K	﹤0.01%	1096

Other funds holding QGEN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Prelude Capital Management's QGEN Position: Q2 2026 in Review

Prelude Capital Management sold out of Qiagen (QGEN) in Q2 2026, closing a stake of 10,124 shares — an estimated $405K sold.

Prelude Capital Management first reported a position in QGEN in Q1 2017 and held it in 11 quarters. The position peaked at $1.08M in Q2 2022. 337 funds tracked by Wall St. Rank hold QGEN as of Q2 2026.

Prelude Capital Management reported no remaining Qiagen position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 10,124 Qiagen shares in Q2 2026, an estimated $405K.
Prelude Capital Management first reported a position in Qiagen in Q1 2017 and held it in 11 quarters.
Prelude Capital Management's Qiagen position peaked at $1.08M in Q2 2022.
337 funds tracked by Wall St. Rank held Qiagen as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.